A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Inclusion Criteria: * Age greater than or equal to 18 years * Diagnosis of AML according to WHO criteria except acute promyelocytic leukemia AND * Refractory AML defined as a failure to achieve CR after 2 cycles of induction chemotherapy or persistence of \> 40% bone marrow blasts after one cycle of chemotherapy induction OR * Relapsed AML defined as any evidence of disease recurrence within 12 months of achieving first CR OR * Relapsed AML after stem cell transplantation 100 days must have elapsed between transplant and emergence of recurrent AML * ECOG performance status \<3 (Appendix 1) Exclusion Criteria: * Abnormal renal function as evidenced by a calculated creatinine clearance ≤ 30ml/min (Cockcroft-Gault formula (Appendix 2) * Abnormal liver function: Bilirubin \>2.0 mg/dl, transaminase more than 2.5x the upper limits of normal * Active systemic infection * Known chronic liver disease * Known diagnosis of human immunodeficiency virus infection (HIV) * Patients who are post-allogeneic transplantation should not have active GVHD greater than grade 1 of skin * Pregnant or breast feeding female subjects